Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1961 1
1968 1
1972 1
1982 5
1983 2
1998 1
2002 1
2004 2
2005 2
2008 2
2009 2
2010 1
2011 1
2012 1
2013 1
2014 1
2015 1
2016 2
2017 2
2018 5
2019 13
2020 10
2021 9
2022 8
2023 8
2024 7
2025 9

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

88 results

Results by year

Filters applied: . Clear all
Page 1
Daratumumab or Active Monitoring for High-Risk Smoldering Multiple Myeloma.
Dimopoulos MA, Voorhees PM, Schjesvold F, Cohen YC, Hungria V, Sandhu I, Lindsay J, Baker RI, Suzuki K, Kosugi H, Levin MD, Beksac M, Stockerl-Goldstein K, Oriol A, Mikala G, Garate G, Theunissen K, Spicka I, Mylin AK, Bringhen S, Uttervall K, Pula B, Medvedova E, Cowan AJ, Moreau P, Mateos MV, Goldschmidt H, Ahmadi T, Sha L, Cortoos A, Katz EG, Rousseau E, Li L, Dennis RM, Carson R, Rajkumar SV; AQUILA Investigators. Dimopoulos MA, et al. N Engl J Med. 2025 May 8;392(18):1777-1788. doi: 10.1056/NEJMoa2409029. Epub 2024 Dec 9. N Engl J Med. 2025. PMID: 39652675 Clinical Trial.
Current Novel Targeted Therapeutic Strategies in Multiple Myeloma.
Lin CH, Tariq MJ, Ullah F, Sannareddy A, Khalid F, Abbas H, Bader A, Samaras C, Valent J, Khouri J, Anwer F, Raza S, Dima D. Lin CH, et al. Among authors: samaras c. Int J Mol Sci. 2024 Jun 4;25(11):6192. doi: 10.3390/ijms25116192. Int J Mol Sci. 2024. PMID: 38892379 Free PMC article. Review.
Pomalidomide/Daratumumab/Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Overall Survival From MM-014.
Bahlis NJ, Samaras C, Reece D, Sebag M, Matous J, Berdeja JG, Shustik J, Schiller GJ, Ganguly S, Song K, Seet CS, Acosta-Rivera M, Bar M, Quick D, Fonseca G, Liu H, Gentili C, Singh P, Siegel D. Bahlis NJ, et al. Among authors: samaras c. Clin Lymphoma Myeloma Leuk. 2024 Dec;24(12):852-862. doi: 10.1016/j.clml.2024.07.014. Epub 2024 Aug 8. Clin Lymphoma Myeloma Leuk. 2024. PMID: 39237427 Free article. Clinical Trial.
Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
Dimopoulos MA, Richardson PG, Bahlis NJ, Grosicki S, Cavo M, Beksaç M, Legieć W, Liberati AM, Goldschmidt H, Belch A, Magen H, Larocca A, Laubach JP, Petrucci MT, Reece D, White D, Mateos MV, Špička I, Lazaroiu M, Berdeja J, Kaufman JL, Jou YM, Ganetsky A, Popa McKiver M, Lonial S, Weisel K; ELOQUENT-1 investigators. Dimopoulos MA, et al. Lancet Haematol. 2022 Jun;9(6):e403-e414. doi: 10.1016/S2352-3026(22)00103-X. Epub 2022 May 9. Lancet Haematol. 2022. PMID: 35550060 Free article. Clinical Trial.
Management of relapsed refractory multiple myeloma: Evidence-based guide to community oncologists.
Mushtaq A, Cheema AY, Ali HM, Shatnawi Y, Ashruf O, Ahmad EN, Lytvynova O, Munir M, Asif MA, Ahmad M, Hassan H, Khan AM, Roy T, Majeed A, Raza S, Mazzoni S, Williams L, Khouri J, Valent J, Samaras C, Rudoni J, Faiman BM, Rice M, Kissam J, Basali D, Anwer F. Mushtaq A, et al. Among authors: samaras c. Blood Rev. 2025 Nov;74:101339. doi: 10.1016/j.blre.2025.101339. Epub 2025 Sep 27. Blood Rev. 2025. PMID: 41027761 Review.
Treatment of relapsed multiple myeloma: Evidence-based recommendations.
Durer C, Durer S, Lee S, Chakraborty R, Malik MN, Rafae A, Zar MA, Kamal A, Rosko N, Samaras C, Valent J, Chaulagain C, Anwer F. Durer C, et al. Among authors: samaras c. Blood Rev. 2020 Jan;39:100616. doi: 10.1016/j.blre.2019.100616. Epub 2019 Aug 31. Blood Rev. 2020. PMID: 31500848 Review.
Suppression to removal, an emerging therapeutic approach for AL amyloidosis: A comprehensive review with early human data and pharmacokinetics of CAEL-101 antibody.
Ashfaque A, Shatnawi Y, Raza S, Basali D, Khouri J, Williams L, Mazzoni S, Samaras C, Hassan H, Acharya U, Chaulagain C, Anwer F. Ashfaque A, et al. Among authors: samaras c. Blood Rev. 2025 Aug;73:101299. doi: 10.1016/j.blre.2025.101299. Epub 2025 May 9. Blood Rev. 2025. PMID: 40382293 Free article. Review.
Monoclonal gammopathy of undetermined significance: A primary care guide.
Khouri J, Samaras C, Valent J, Mejia Garcia A, Faiman B, Mathur S, Hamilton K, Nakashima M, Kalaycio M. Khouri J, et al. Among authors: samaras c. Cleve Clin J Med. 2019 Jan;86(1):39-46. doi: 10.3949/ccjm.86a.17133. Cleve Clin J Med. 2019. PMID: 30624183 Free article. Review.
88 results